CommercialCoverageHigh impact
Policy Criteria Changes
Arkansas Blue Cross Blue Shield·AR · Oncology, Ophthalmology, Neurology +1 more·Medical Policy
Effective date
Dec 1, 2025
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross updated preferred/non-preferred drug lists for several specialty medications including cancer treatments, eye injections, and multiple sclerosis drugs. Most changes require switching to preferred products and new prior authorization requirements for certain eye medications starting December 1, 2025 and January 1, 2026.
Action Required
By December 1, 2025: Update billing system to reflect preferred products - use Mvasi or Zirabev instead of Avastin for bevacizumab claims. By January 1, 2026: Implement prior authorization requirements for Eylea, Eylea HD, and Yesafili eye injections. Update encounter forms to show preferred products: Byooviz, Lucentis, Pavblu, Vabysmo for ophthalmic use. Train providers on new biosimilar options for denosumab including Osenvelt, Stoboclo, and Xbryk. Claims using non-preferred products may face coverage restrictions or higher patient costs.